Abstract
There is a strong association between chronic inflammation and cancer formation. This correlation has been well observed in patients with long standing inflammatory bowel disease (IBD) who are at high risk of colorectal cancer (CRC). At present, there is a lack of good markers for predicting the progression from normal to neoplastic mucosa in patients with IBD. IBD patients who are ‘at-risk’ of CRC should be identified, evaluated and should also be enrolled in surveillance program, regardless of their disease activity. Early identification of dysplasia and its appropriate management using endoscopic techniques or surgery are essential in patients with long-standing IBD, to minimize CRC morbidity and mortality. Gastroenterologists should work along with experienced, specialised gastrointestinal pathologists, surgeons and with fully informed and compliant IBD patients' to ensure the success of surveillance programme in early detection of CRC.
Keywords: Inflammatory bowel disease, Ulcerative Colitis, Surveillance colonoscopy, dysplasia, colorectal cancer, colectomy, Crohn's disease, NSAIDs, Ursodeoxycholic acid, Chromoendoscopy, Narrow-Band Imging, Confocal Endomicroscopy, DALMs
Current Drug Targets
Title: How to Manage the Risk of Colorectal Cancer in Ulcerative Colitis
Volume: 12 Issue: 10
Author(s): Raja Affendi Raja Ali and Laurence John Egan
Affiliation:
Keywords: Inflammatory bowel disease, Ulcerative Colitis, Surveillance colonoscopy, dysplasia, colorectal cancer, colectomy, Crohn's disease, NSAIDs, Ursodeoxycholic acid, Chromoendoscopy, Narrow-Band Imging, Confocal Endomicroscopy, DALMs
Abstract: There is a strong association between chronic inflammation and cancer formation. This correlation has been well observed in patients with long standing inflammatory bowel disease (IBD) who are at high risk of colorectal cancer (CRC). At present, there is a lack of good markers for predicting the progression from normal to neoplastic mucosa in patients with IBD. IBD patients who are ‘at-risk’ of CRC should be identified, evaluated and should also be enrolled in surveillance program, regardless of their disease activity. Early identification of dysplasia and its appropriate management using endoscopic techniques or surgery are essential in patients with long-standing IBD, to minimize CRC morbidity and mortality. Gastroenterologists should work along with experienced, specialised gastrointestinal pathologists, surgeons and with fully informed and compliant IBD patients' to ensure the success of surveillance programme in early detection of CRC.
Export Options
About this article
Cite this article as:
Affendi Raja Ali Raja and John Egan Laurence, How to Manage the Risk of Colorectal Cancer in Ulcerative Colitis, Current Drug Targets 2011; 12 (10) . https://dx.doi.org/10.2174/138945011796818270
DOI https://dx.doi.org/10.2174/138945011796818270 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Plant-Type Ferredoxin-NADP+ Reductase/Ferredoxin Redox System as a Possible Drug Target Against Apicomplexan Human Parasites
Current Pharmaceutical Design Immunotoxicity and Immunogenicity of Biopharmaceuticals: Design Concepts and Safety Assessment
Current Drug Safety Understanding Recognition and Self-assembly in Biology using the Chemist´s Toolbox. Insight into Medicinal Chemistry
Current Topics in Medicinal Chemistry The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Current Drug Targets A Review on Theragnostic Applications of Micrornas and Long Non- Coding RNAs in Colorectal Cancer
Current Topics in Medicinal Chemistry Patents in Cancer Stem Cells
Recent Patents on Biomarkers Silymarin in the Prevention and Treatment of Liver Diseases and Primary Liver Cancer
Current Pharmaceutical Biotechnology Molecular Mistletoe Therapy: Friend or Foe in Established Anti-Tumor Protocols? A Multicenter, Controlled, Retrospective Pharmaco-Epidemiological Study in Pancreas Cancer
Current Molecular Medicine TRP Channels and Cancer: New Targets for Diagnosis and Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets From Adipose Tissue Protein Secretion to Adipopharmacology of Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Novel Agents in the Management of Lung Cancer
Current Medicinal Chemistry Histone Deacetylases as Targets for Dietary Cancer Preventive Agents: Lessons Learned with Butyrate, Diallyl Disulfide, and Sulforaphane
Current Drug Targets Chemotherapy in Addition to Preoperative Radiotherapy in Locally Advanced Rectal Cancer – A Systematic Overview
Reviews on Recent Clinical Trials Role of Vitamins in Human Health and Nutrition: Sources and Morbidity
Current Nutrition & Food Science Targeting Antioxidants to Mitochondria: A Potential New Therapeutic Strategy for Cardiovascular Diseases
Current Pharmaceutical Design Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression
Current Drug Metabolism Clinical Applications of <sup>18</sup>F-FDG PET/CT in Monitoring Anti-cancer Therapies
Current Pharmaceutical Biotechnology Computational Approaches for Translational Oncology: Concepts and Patents
Recent Patents on Anti-Cancer Drug Discovery